Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B

Kuan LI; Huibin NING; Huiming JIN; Zhen PENG; Jia SHANG

doi:10.3969/j.issn.1001-5256.2023.08.009

Volume 39 Issue 8

Aug. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(8): 1819-1824

PDF( 1687 KB)

Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2023.08.009

Department of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou 450003, China

Research funding:

China Research on Reducing the Incidence of Liver Cancer in Hepatitis B Patients (Oasis) Project (LZGC2022-03)

More Information

Corresponding author: SHANG Jia, shangjia666@126.com (ORCID: 0000-0001-9197-8773)
Received Date: 2022-11-29
Accepted Date: 2023-02-01
Published Date: 2023-08-20

Abstract

Abstract

Objective To investigate the effect of pegylated interferon α-2b (PEG-IFNα-2b) on HBsAg clearance in the treatment of chronic hepatitis B (CHB) in a real-world setting. Methods A retrospective analysis was performed for 411 CHB patients who attended Department of Infectious Diseases, Henan Provincial People's Hospital, from June 2017 to January 2021, and all these patients were treated with PEG-IFNα-2b. Related clinical data were collected, including sex, age, antiviral treatment regimen, baseline HBsAg level, and post-treatment HBsAg level, and HBsAg clearance rate was observed at 24, 48, and 96 weeks. HBsAg clearance rate at different time points of follow-up was compared between the patients with different baseline HBsAg levels (< 500 IU/mL, 500-1 500 IU/mL, and 1 501-5 000 IU/mL) or with the use of PEG-IFNα-2b after different previous treatment conditions and regimens. The independent-samples t test was used for comparison of continuous data between two groups, and the chi-square test and the trend chi-square test were used for comparison of categorical data between groups. Results The HBsAg clearance rate was 9.9% (26/263) in the patients who completed 24 weeks of treatment, 19.7% (25/127) in the patients who completed 48 weeks of treatment, and 41.7% (30/72) in the patients who completed 96 weeks of treatment. There was a significant difference in HBsAg clearance rate between the patients with different baseline HBsAg levels at 24, 48, and 96 weeks of treatment (χ²=52.265, 32.764, and 30.918, all P < 0.01), and HBsAg clearance rate gradually increased over the time of treatment (χ_trend²=44.517, 29.147, and 22.260, all P < 0.01). Compared with the HBsAg < 500 IU/mL group, the 500-1 500 IU/mL group and the 1 501-5 000 IU/mL group had a significant reduction in HBsAg clearance rate at 24, 48, and 96 weeks of follow-up (all P < 0.001). As for the comparison of the patients with different treatment conditions (previously untreated or treatment-experienced) and treatment regimens (monotherapy or combined therapy) at 24, 48, and 96 weeks of treatment, there was a significant difference in fame/female ration between the previously untreated group and the treatment-experienced group (χ²=5.029, P=0.025), and there was no significant difference in HBsAg clearance rate between the previously untreated group and the treatment-experienced group and between the monotherapy group and the combined therapy group (all P > 0.05). Conclusion PEG-IFNα-2b has a marked effect on HBsAg clearance in the treatment of CHB, and patients with a lower baseline HBsAg level tend to have a higher HBsAg clearance rate. HBsAg clearance rate tends to increase over the time of treatment. A baseline HBsAg level of 500 IU/mL can be used as the cut-off point to identify the dominant population.
- Pegylated Interferon α-2b,
- Hepatitis B, Chronic,
- Hepatitis B Surface Antigens

FullText(HTML)

References(25)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	National Health Commission. China health statistical yearbook 2020[M]. Beijing: China Union Medical College Press, 2020. 国家卫生健康委员会. 2020中国卫生健康统计年鉴[M]. 北京: 中国协和医科大学出版社, 2020.
[3]	Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL]. [2020-12-15]. https://www.iarc.fr/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/.
[4]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[5]	PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study[J]. Gut, 2011, 60(8): 1109-1116. DOI: 10.1136/gut.2010.221846.
[6]	ZHANG W, WANG X, WANG Y, et al. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up[J]. Medicine (Baltimore), 2017, 96(44): e8454. DOI: 10.1097/MD.0000000000008454.
[7]	CHO JY, PAIK YH, SOHN W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease[J]. Gut, 2014, 63(12): 1943-1950. DOI: 10.1136/gutjnl-2013-306409.
[8]	ZHOU TC, LAI X, FENG MH, et al. Systematic review and meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion[J]. J Viral Hepat, 2018, 25(10): 1172-1179. DOI: 10.1111/jvh.12928.
[9]	LIU F, WANG XW, CHEN L, et al. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance[J]. Aliment Pharmacol Ther, 2016, 43(12): 1253-1261. DOI: 10.1111/apt.13634.
[10]	ZHANG XY, JIA RR, XIANG X, et al. Letter: older age and male gender increase the risk of hepatocellular carcinoma after hepatitis B surface antigen (HBsAg) seroclearance[J]. Aliment Pharmacol Ther, 2017, 46(9): 906-908. DOI: 10.1111/apt.14272.
[11]	YIP TC, CHAN HL, WONG VW, et al. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance[J]. J Hepatol, 2017, 67(5): 902-908. DOI: 10.1016/j.jhep.2017.06.019.
[12]	TATEDA K, SUZUKI F, KOBAYASHI M. Predictive factors associated with hepatocellular carcinoma incidence and mortality after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B[J]. Hepatology, October, 2018, AASLD Abstract(oral 213).
[13]	LIAW YF. Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat[J]. Hepatology, 2021, 73(2): 843-852. DOI: 10.1002/hep.31525.
[14]	LI M, ZHANG L, LU Y, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferonα-2a[J]. Virol Sin, 2021, 36(2): 311-320. DOI: 10.1007/s12250-020-00290-7.
[15]	ZHANG WH, ZHANG DZ, DOU XG, et al. Consensus on pegylated interferon alpha in treatment of chronic hepatitis B[J]. Chin J Hepatol, 2017, 25(9): 678-686. DOI: 10.3760/cma.j.issn.1007-3418.2017.09.007. 张文宏, 张大志, 窦晓光, 等. 聚乙二醇干扰素α治疗慢性乙型肝炎专家共识[J]. 中华肝脏病杂志, 2017, 25(9): 678-686. DOI: 10.3760/cma.j.issn.1007-3418.2017.09.007.
[16]	Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
[17]	HOU FQ, YIN YL, ZENG LY, et al. Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients[J]. Chin J Hepatol, 2017, 25(8): 589-596. DOI: 10.3760/cma.j.issn.1007-3418.2017.08.007. 侯凤琴, 尹亚琳, 曾玲英, 等. 聚乙二醇干扰素α-2b(Y型, 40kD)注射液治疗HBeAg阳性慢性乙型肝炎患者的疗效和安全性分析[J]. 中华肝脏病杂志, 2017, 25(8): 589-596. DOI: 10.3760/cma.j.issn.1007-3418.2017.08.007.
[18]	NING Q, HAN M, SUN Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)[J]. J Hepatol, 2014, 61(4): 777-784. DOI: 10.1016/j.jhep.2014.05.044.
[19]	HAN M, JIANG J, HOU J, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study[J]. Antivir Ther, 2016, 21(4): 337-344. DOI: 10.3851/IMP3019.
[20]	LI GJ, YU YQ, CHEN SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment[J]. Antimicrob Agents Chemother, 2015, 59(7): 4121-4128. DOI: 10.1128/AAC.00249-15.
[21]	HU P, SHANG J, ZHANG W, et al. HBsAg Loss with Peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study[J]. J Clin Transl Hepatol, 2018, 6(1): 25-34. DOI: 10.14218/JCTH.2017.00072.
[22]	ZENG QL, YU ZJ, SHANG J, et al. Short-term peginterferon-induced high functional cure rate in inactive chronic hepatitis B virus carriers with low surface antigen levels[J]. Open Forum Infect Dis, 2020, 7(6): ofaa208. DOI: 10.1093/ofid/ofaa208.
[23]	TANGKIJVANICH P, CHITTMITTRAPRAP S, POOVORAWAN K, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response[J]. J Viral Hepat, 2016, 23(6): 427-438. DOI: 10.1111/jvh.12467.
[24]	LIU J, WANG T, ZHANG W, et al. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis[J]. Hepatol Int, 2020, 14(6): 958-972. DOI: 10.1007/s12072-020-10099-x.
[25]	CHOI H, van CAMPENHOUT M, van VUUREN AJ, et al. Ultra-long-term follow-up of interferon alfa treatment for HBeAg-positive chronic hepatitis B virus infection[J]. Clin Gastroenterol Hepatol, 2021, 19(9): 1933-1940. e1. DOI: 10.1016/j.cgh.2020.09.004.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (402) PDF downloads(90)

Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2023.08.009

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content